

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in this application:

1. (Currently Amended) A molecule comprising the antigen-binding portion of an isolated antibody which has an increased affinity for a fibroblast growth factor receptor 3 (FGFR3) and which binds and blocks ligand-independent activation of said a fibroblast growth factor receptor 3 (FGFR3) having an extracellular portion which is encoded by SEQ ID NO: 4.

Claims 2-6. (Cancelled)

7. (Currently Amended) The molecule according to claim 1[[6]], comprising a V_H region and a V_L region, respectively, ~~selected from SEQ ID NO: 96 and SEQ ID NO: 85; SEQ ID NO: 98 and SEQ ID NO: 87; and having~~ SEQ ID NO: 106 and SEQ ID NO: 95.

8. (Currently Amended) The molecule according to claim 1[[6]], comprising a V_H-CDR3 region and a V_L-CDR3 region, respectively, ~~selected from SEQ ID NO: 8 and SEQ ID NO: 9; SEQ ID NO: 12 and SEQ ID NO: 13; and having~~ SEQ ID NO: 24 and SEQ ID NO: 25.

Claim 9. (Cancelled)

10. (Currently Amended) A pharmaceutical composition, comprising as an active ingredient at least one molecule according to claim 1[[6]] and a pharmaceutically acceptable carrier, excipient, or auxiliary agent.

Claims 11-30. (Cancelled)

31. (Previously Presented) A kit comprising the molecule of claim 1, at least one reagent suitable for detecting the presence of said molecule when bound to said FGFR3 and instructions for use.

32. (Previously Presented, Withdrawn) A method for treating or inhibiting a skeletal dysplasia or a craniosynostosis disorder, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 10 to a subject in need thereof.

33. (Withdrawn) The method according to claim 32, wherein the skeletal dysplasia is selected from achondroplasia, thanatophoric dysplasia (TD), hypochondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) dysplasia.

34. (Withdrawn) The method according to claim 33, wherein said skeletal dysplasia is achondroplasia.

35. (Withdrawn) The method according to claim 32, wherein the craniosynostosis disorder is Muenke coronal craniosynostosis or Crouzon syndrome with acanthosis nigricans.

Claims 36-37. (Cancelled)

38. (Previously Presented, Withdrawn) A method for treating or inhibiting a cell proliferative disease or disorder associated with abnormal FGFR3 activity, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 10 to a subject in need thereof.

39. (Withdrawn) The method according to claim 38, wherein the cell proliferative disease or disorder is selected from solid tumors, non-solid cancer or tumor progression,

40. (Withdrawn) The method according to claim 39, wherein the tumor progression is the progression of transitional cell carcinoma, mammary carcinoma, osteosarcoma or chondrosarcoma.

41. (Withdrawn) The method according to claim 39, wherein the non-solid cancer is a hematopoietic malignancy.

42. (Withdrawn) The method according to claim 41, wherein the hematopoietic malignancy is multiple myeloma.

43. (Previously Presented, Withdrawn) The method according to claim 38, wherein the disorder is associated with the action of a constitutively activated receptor protein tyrosine kinase.

44. (Previously Presented, Withdrawn) A method for screening a molecule comprising the antigen-binding portion of an antibody according to claim 1, comprising: providing a library of antigen binding fragments; screening a library of antigen binding fragments for binding to a dimeric form of a FGFR3; identifying an antigen binding fragment which binds to the dimeric form of the FGFR3 as a candidate molecule for blocking activation of the FGFR3; and determining whether the candidate molecule blocks constitutive and/or ligand-dependent activation of FGFR3 in a cell.

Claims 45-49. (Cancelled)